Biomea Fusion Announces Leadership Transition
Board member Mick Hitchcock named interim CEO replacing Thomas Butler.
COO and President Ramses Erdtmann continuing at Biomea in current role.
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea,' or the 'Company') (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately.
'As a long-time member of Biomea's Board, I've had the privilege of closely supporting the company's mission and strategic direction,' said Michael J.M. Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member of Biomea Fusion. 'I'm honored to step into this leadership role at such a promising moment in our development. The recent clinical progress with icovamenib, especially the positive Phase II data in insulin-deficient patients, marks a major milestone in our pursuit of a disease-modifying therapy for diabetes. I look forward to working even more closely with the exceptional Biomea team as we advance late-stage development efforts, prepare for regulatory engagement, and continue building a pipeline of innovative covalent therapies. Our mission remains clear: We aim to cure, and I'm committed to helping lead us there.'
Dr. Michael J. M. Hitchcock, Ph.D. (Mick) has served as a member of the Company's board since March 2021. Dr. Hitchcock is currently a Past Chair of the University of Nevada, Reno (UNR) Foundation and Adjunct Professor of Microbiology at UNR Medical School, a position in which he has served since July 2016. Dr Hitchcock's career in pharmaceutical research and development initially began with Bristol-Myers Squibb, where he served in several infectious disease research and project planning roles from 1980 through 1993. He joined Gilead Sciences, Inc. in 1993 and during his 27 years with the Company, he held a variety of positions, including vice president roles with responsibility for project and portfolio management, alliance management, strategic planning, medical affairs and specific areas of research. He also served as Senior Advisor at Gilead from 2009 through November 2019. During his career, he was involved in the development and commercialization of a number of anti-infective agents, primarily antivirals for treatment of HIV, HBV, influenza, CMV and other viral diseases. Dr. Hitchcock holds a Ph.D. in microbiology from the University of Melbourne, Australia and B.Sc. and M.Sc. degrees in biochemistry from the University of Manchester Institute of Science and Technology, England. He also conducted post-doctoral research at Georgetown University and NIH prior to joining industry.
Biomea continues to develop its product candidates for the treatment of diabetes based on its novel menin inhibition science.
'On behalf of the Board, we would like to thank Tom Butler for his important contributions to Biomea and his leadership to date,' said Dr. Hitchcock.
About Biomea FusionBiomea is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic disease. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. Contact: Meichiel Jennifer Weiss Sr. Director, Investor Relations and Corporate DevelopmentIR@biomeafusion.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
10 minutes ago
- Hamilton Spectator
Bombardier's Record-Setting Global 7500 Aircraft Earns New Speed Record Between Montréal and Paris
PARIS, June 16, 2025 (GLOBE NEWSWIRE) — Bombardier is proud to announce that its flagship aircraft, the Global 7500 , has set a new speed record on a mission departing from Pierre Elliott Trudeau International Airport in Montreal, and landing at Paris-Le Bourget Airport. The Global 7500 , renowned for its unparalleled capabilities, logged another record with a top speed of over 1,000 km/hr during its flight to Paris and completed the record in 5 hours and 30 minutes. This accomplishment comes as the Bombardier team is gearing up to host customers at the International Paris Air Show, with the company's presence anchored by Bombardier Defense. 'The Global 7500 performs at the highest levels across the board, in real-world situations. Bombardier takes great pride in completing meaningful speed records, like this latest one, during regular day-to-day operations with passengers, baggage and cargo, setting it apart from peers,' said Éric Martel, President and CEO of Bombardier. 'As we are getting ready for the entry into service of the Global 8000 aircraft later this year, the Global 7500 aircraft keeps demonstrating its superiority on all fronts, from its signature smooth ride to its industry-leading performance and landing capabilities.' Bombardier has a proud history of setting speed records with the Global 7500 . Only a few weeks ago, the Global 7500 reclaimed the speed record from Paris to Montreal, completing the flight in less than 6 hours. Previous achievements include breaking the record for the longest mission ever flown by a purpose-built business jet, covering 8,225 nautical miles non-stop from Sydney to Detroit. These milestones underscore Bombardier's commitment to innovation and excellence in aviation. Designed with the needs of business travelers in mind, the Global 7500 offers maximum range of 7,700 nautical miles and is designed to offer unmatched long-haul travel capabilities. It boasts a spacious and refined cabin that can be customized to suit the preferences and needs of each customer. The aircraft features four distinct living spaces, including a full-size kitchen, providing the ultimate comfort and convenience. Its state-of-the-art connectivity options and ergonomic seating make it an ideal environment for productivity and relaxation, ensuring that passengers arrive at their destination refreshed and ready to take on their business endeavors. About Bombardier At Bombardier ( we design, build, modify and maintain the world's best-performing aircraft for the world's most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs. For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it. Bombardier customers operate a fleet of more than 5,100 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service facilities across six countries. Bombardier's performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico. In 2024, Bombardier was honoured with the prestigious 'Red Dot: Best of the Best' award for Brands and Communication Design. For Information For corporate news and information, including Bombardier's Sustainability report, as well as the company's initiative to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book-and-Claim system visit . Learn more about Bombardier's industry-leading products and customer service network at . Follow us on X @Bombardier. Media Contacts General media contact webform Christina Lemyre McCraw +1-514-497-4928 Bombardier, Global, Global 7500 and Global 8000 are registered or unregistered trademarks of Bombardier Inc. or its subsidiaries. A photo accompanying this announcement is available at
Business Insider
2 hours ago
- Business Insider
Upcoming Stock Splits This Week (June 16 to June 20)
These are the upcoming stock splits for the week of June 16 to June 20, based on TipRanks' Stock Splits Calendar. A stock split occurs when a company issues additional shares to existing investors, increasing the total share count without changing its overall market value. The result is a lower price per share, making the stock appear more affordable to everyday investors. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter On the flip side, a reverse stock split shrinks the share count by combining existing shares, driving the price per share higher while keeping the total valuation intact. Companies often use this move to stay in compliance with stock exchange rules, particularly when their share price is hovering near delisting thresholds like Nasdaq's minimum requirement. Whether to attract investor attention or to meet listing standards, these maneuvers can offer important clues about a company's current priorities and future strategy. Let's take a look at the upcoming stock splits for the week. Jianzhi Education Technology Group (JZ) – Beijing‑based Jianzhi is a digital education provider offering online learning platforms and professional development content to higher education institutions and individuals across China. On June 12, the company announced an upcoming 1‑for‑10 reverse ADS split to boost its ADS trading price and maintain Nasdaq listing compliance. The split is scheduled to be effective at the start of trading on June 16. GlycoMimetics (GLYC) – U.S.-based GlycoMimetics is a clinical-stage biotech company developing treatments for sickle cell disease and cancer by targeting cell adhesion. On June 5, the company announced a 1-for-100 reverse stock split to support its planned merger with Crescent Biopharma. The split will take effect June 16, with shares trading under the new ticker CBIO as the combined company moves forward. Neo-Concept International Group Holdings (NCI) – Neo-Concept is a Hong Kong-headquartered apparel supplier and importer serving global e-commerce platforms. Following shareholder approval at its May 9 meeting, the company is rolling out a 1-for-5 reverse share consolidation. The adjustment takes place June 16. Shuttle Pharmaceuticals (SHPH) – Shuttle Pharmaceuticals is advancing a pipeline of radiation-sensitizing drugs aimed at improving cancer outcomes. On June 12, it unveiled a 1-for-25 reverse stock split to bring its share price back in line with Nasdaq's minimum bid requirement. The split becomes effective June 16, with SHPH shares trading on a split-adjusted basis that morning. Jeffs' Brands (JFBR) – Jeffs' Brands operates data-driven e-commerce brands across major online marketplaces, including Amazon. After securing shareholder approval, the company announced on June 12 a 1-for-17 reverse stock split aimed at maintaining its Nasdaq listing. The change goes live June 16. Security Matters (SMX) – Dublin-based Security Matters offers advanced digital tracking and authentication solutions for supply chains and product integrity. The company is implementing a 4.1-for-1 reverse stock split, which was approved earlier this spring and formally announced on June 12. The split is scheduled to take effect June 16. Glucotrack (GCTK) – Glucotrack is a med-tech innovator developing non-invasive glucose monitoring solutions for diabetes management. To meet Nasdaq compliance standards, the company announced a 1-for-60 reverse stock split on June 12, following prior shareholder approval at its May 22 annual meeting. The split becomes effective June 16. Regencell Bioscience Holdings (RGC) – Hong Kong–based Regencell is on a mission to treat neurocognitive disorders like ADHD and autism using traditional Chinese medicine. On June 2, the company unveiled a 38-for-1 forward stock split to boost liquidity and attract retail interest. Shareholders of record as of June 12 received their additional shares on June 13, and RGC began trading on a split-adjusted basis on June 16. Sensei Biotherapeutics (SNSE) – Sensei is a clinical-stage biotech based in Boston, developing next-gen immunotherapies to take on cancer. On June 13, the company announced a 1-for-20 reverse stock split in an effort to meet Nasdaq's minimum price threshold and maintain its listing. The split takes effect on June 16, with adjusted trading kicking off on June 17. RAPT Therapeutics (RAPT) – RAPT is advancing innovative therapies targeting inflammatory and autoimmune diseases. On June 13, the company rolled out a 1-for-8 reverse stock split aimed at reshaping its capital structure. The move becomes official on June 16, with split-adjusted shares starting to trade on June 17. FibroGen (FGEN) – FibroGen is a biotech company focused on fibrosis and other serious diseases. On June 12, it announced a 1-for-25 reverse stock split designed to help the stock climb back above the Nasdaq's minimum bid requirement. The split becomes effective on June 16, with trading on a split-adjusted basis beginning June 17. Interactive Brokers Group (IBKR) – A powerhouse in online trading, Interactive Brokers is known for serving active investors with low-cost, high-tech tools. On April 15, the company declared a 4-for-1 forward stock split to make shares more accessible to a broader investor base. Shareholders of record on June 16 received the extra shares on June 17, and IBKR stock began trading at the new price on June 18. TipRanks Stock Splits Calendar.
Yahoo
3 hours ago
- Yahoo
Veteran analyst sends surprising message on stocks, bonds, and gold
Veteran analyst sends surprising message on stocks, bonds, and gold originally appeared on TheStreet. The stock market rally has been impressive. Since President Donald Trump paused most reciprocal tariffs on April 9, only days after announcing them, stocks have soared. The S&P 500 has gained about 20%, while the tech-stock heavy Nasdaq Composite is up 27%. Those returns in such a short span significantly outpace the average 10% annual return for stocks since 1928. Stocks haven't been the only winner. Gold has also notched impressive returns this year. The yellow metal has rallied 30% in 2025 as investors have sought to insulate risk amid growing economic concerns surrounding debt and the impact of tariffs on one big disappointment this year: Treasury bonds. They've tumbled, sending bond yields soaring, as global investors have soured on financing America's insatiable appetite for spending. The market action has captured the attention of many, including veteran commodities and futures analyst Carley Garner. Garner has been professionally navigating these markets for 20 years, and her track record includes accurately predicting the stock rally in 2023 and last year's decline in oil prices. Garner updated her outlook on stocks, gold, and bonds, and her takeaway may surprise you. Stocks' rally since the lows in early April likely surprised many, given significant economic risks remain. While inflation has retreated below 3% from over 8% in 2022, price increases over the past years have cash-strapped consumers, causing them to shift spending from discretionary purchases to problem has been compounded by an uptick in unemployment, which has increased to 4.2% from 3.4% in 2023, partly due to higher interest rates designed to crimp inflation. According to Challenger, Gray, & Christmas, U.S. companies have laid off 696,309 workers this year through May, up 80% from one year ago. The situation isn't likely to get much better for workers. While Trump paused many reciprocal tariffs in April, key tariffs remain, including a 25% tariff on Canada and Mexico and autos, a 10% tariff on all imports, and 30% tariff on China (total tariffs on China, including those put in place during President Trump's first term exceed 50%). The remaining tariffs, and potential for more after the 90-day pause expires, could fuel inflation later this year, particularly in retail, which sources everything from clothing to electronics from overseas. The risk of inflation alongside job losses suggests America could go headlong into a period of stagflation or recession. Despite those risks, the S&P 500 and Nasdaq Composite have notched remarkable gains. Investors who quickly sold amid tariff announcements earlier this year have been left behind, and as a result, they're buying every dip to regain their exposure. One major exception? Warren Buffett. The Oracle of Omaha has increased Berkshire Hathaway's cash position, choosing to collect guaranteed fixed income from T-bills rather than leap back into the stock market amid the uncertainty. Exiting the first quarter, Warren Buffett's cash stockpile eclipsed $347 billion, a record, and more than double the levels exiting 2023. The rallies in stocks and gold may continue, but like Buffett, Carley Garner doesn't see the risk-to-reward as overly compelling in stocks. She's also become bearish on gold relative to bonds, given that gold has moved significantly higher and, unlike bonds, doesn't pay dividends. "While I believe the S&P 500 can easily reach 6300 to 6400, the downside risk might be outsized relative to the potential reward," wrote Garner on TheStreet Pro. "Since 1928, the S&P 500 has returned an average annual rate of 10%; however, in recent years, the average return has been abnormally high, at approximately 14%. There is a good chance that, like the dot-com era, we have pulled forward gains and could be on the verge of a 'returnless' market in the coming years." Garner points to a key measure favored by Warren Buffett regarding stock market valuation as evidence that stocks are over their skis. More Experts: Fed official sends strong message about interest-rate cuts Billionaire fund manager sends surprising message on trade deficit Hedge-fund manager sees U.S. becoming Greece "The Warren Buffett Indicator measures the total stock market value vs. the GDP," wrote Garner. "Since 1950, the stock market has only been this overstretched a few other times. Not surprisingly, the dot-com bubble was one of those times. Historically, this indicator has not been the time to hit the gas on risk assets. It has been the opposite." The arguable overvaluation of stocks could mean the risk of a reckoning is high enough to concentrate on other assets. However, gold may not be the best bet, given it's already made a big move higher. Instead, it's Treasury bonds that Garner believes offer the best chance for upside. "There is only one [of these assets] near a two-decade low in valuation: Treasuries," writes Garner. "Except for some forms of real estate, it is the only asset that yields an attractive income stream. Lastly, Treasuries are the least risky asset class in the world but the market is treating the securities as anything but." Garner points out that people were flocking to own bonds with paltry yields only five years ago. Now, they're shunning yields near 4.5%. Many are hesitant to own bonds despite the high yields, fearing that bonds will continue to drop, sending yields even higher, as the U.S. debt load rises. While it's true that lower bond values could mean short-term losses, Garner views the risk of a U.S. default as unlikely, suggesting that those holding Treasuries to maturity will be fine, and pocket healthy income along the way. "Historically, there have been two other instances in history when stocks were as overvalued as they are now relative to bonds. Or, alternatively, bonds were this undervalued relative to stocks," wrote Garner. "Such opportunities have only arisen once every two decades, and they have proven to be significant inflection points in both stocks (the beginning of prolonged underperformance) and bonds (the start of a period of capital gains to enhance interest earned). This metric has been similarly favoring bonds since the initial collapse in 2023, so instant satisfaction shouldn't be expected, but patience will likely pay off."Veteran analyst sends surprising message on stocks, bonds, and gold first appeared on TheStreet on Jun 15, 2025 This story was originally reported by TheStreet on Jun 15, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
